PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.28%
Revenue growth of 4.28% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
3.84%
Gross profit growth of 3.84% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
-5.56%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
0.34%
Positive operating income growth while Medical - Pharmaceuticals is negative. Peter Lynch would spot a big relative advantage here.
-15.18%
Negative net income growth while Medical - Pharmaceuticals median is 2.83%. Seth Klarman would investigate factors dragging net income down.
-15.18%
Negative EPS growth while Medical - Pharmaceuticals median is 7.89%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-15.18%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 8.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.00%
Share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.13%. Joel Greenblatt would applaud significant buybacks if they are value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
48.93%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 4.57%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
63.76%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 18.08%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
39.15%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 9.60%. Joel Greenblatt might see a short-term competitive advantage at play.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.40%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 17.48% over a decade. Joel Greenblatt might see a standout compounder of earnings.
56.52%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 9.65%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
44.96%
3Y net income/share CAGR of 44.96% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a small advantage that can be scaled further.
No Data
No Data available this quarter, please select a different quarter.
137.78%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 62.59%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
66.52%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 28.55%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
-100.00%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-98.55%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-1.93%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
0.74%
We expand assets while Medical - Pharmaceuticals is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
3.67%
BV/share growth of 3.67% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-38.23%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
102.83%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.